Plus Therapeutics Presented Data In Podium Presentation Updating The Progress Of Its ReSPECT-LM Trial Of Rhenium Obisbemeda In Leptomeningeal Disease At The 2024 Society For NeuroOncology/American Society For Clinical Oncology CNS Metastases Conference
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics presented data on its ReSPECT-LM trial of Rhenium Obisbemeda in leptomeningeal disease at the 2024 Society for NeuroOncology/American Society for Clinical Oncology CNS Metastases Conference.
August 12, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics presented promising data on its ReSPECT-LM trial of Rhenium Obisbemeda in leptomeningeal disease at a major oncology conference.
The presentation of promising data at a major oncology conference is likely to boost investor confidence and positively impact the stock price of Plus Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100